UY31886A - Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente - Google Patents

Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente

Info

Publication number
UY31886A
UY31886A UY0001031886A UY31886A UY31886A UY 31886 A UY31886 A UY 31886A UY 0001031886 A UY0001031886 A UY 0001031886A UY 31886 A UY31886 A UY 31886A UY 31886 A UY31886 A UY 31886A
Authority
UY
Uruguay
Prior art keywords
dronedarone
prevention
preparation
permanent
fibrilation
Prior art date
Application number
UY0001031886A
Other languages
English (en)
Inventor
Van Eickels Martin
Gaudin Christophe
Hamdani Nacera
Davide Radzik
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31886A publication Critical patent/UY31886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)

Abstract

Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente.
UY0001031886A 2008-06-10 2009-06-10 Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente UY31886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6026308P 2008-06-10 2008-06-10
EP08290531A EP2133074A1 (en) 2008-06-10 2008-06-10 Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation

Publications (1)

Publication Number Publication Date
UY31886A true UY31886A (es) 2010-01-29

Family

ID=39731657

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031886A UY31886A (es) 2008-06-10 2009-06-10 Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente

Country Status (24)

Country Link
US (1) US20110166220A1 (es)
EP (2) EP2133074A1 (es)
JP (1) JP2011522876A (es)
KR (1) KR20110026422A (es)
CN (1) CN102056603A (es)
AR (1) AR072069A1 (es)
AU (1) AU2009259009A1 (es)
CA (1) CA2727326A1 (es)
CL (1) CL2010001422A1 (es)
CO (1) CO6280479A2 (es)
CR (1) CR11829A (es)
DO (1) DOP2010000365A (es)
EA (1) EA201071378A1 (es)
EC (1) ECSP10010666A (es)
IL (1) IL209791A0 (es)
MA (1) MA32462B1 (es)
MX (1) MX2010013698A (es)
NI (1) NI201000211A (es)
PE (1) PE20110055A1 (es)
SV (1) SV2010003756A (es)
TW (1) TW201002676A (es)
UY (1) UY31886A (es)
WO (1) WO2009150535A1 (es)
ZA (1) ZA201008871B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102065855A (zh) 2008-04-17 2011-05-18 赛诺菲-安万特 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
AU2014274638B2 (en) * 2009-12-21 2016-09-15 Gilead Sciences, Inc. Method of treating atrial fibrillation
TWI508726B (zh) * 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
WO2011141888A1 (en) * 2010-05-13 2011-11-17 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with permanent atrial fibrillation
EP2387996A1 (en) * 2010-05-17 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
EP2387997A1 (en) * 2010-05-18 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2012020377A1 (en) * 2010-08-11 2012-02-16 Sanofi Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone
EP3326616B1 (en) * 2011-06-03 2021-07-28 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
EP2543363A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
EP2543362A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts
EP2543361A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
CN112336445B (zh) * 2019-12-26 2021-11-26 上海微创电生理医疗科技股份有限公司 一种消融系统及其神经探测设备

Also Published As

Publication number Publication date
WO2009150535A1 (en) 2009-12-17
AU2009259009A1 (en) 2009-12-17
EP2300001A1 (en) 2011-03-30
SV2010003756A (es) 2011-03-15
CR11829A (es) 2011-01-11
JP2011522876A (ja) 2011-08-04
IL209791A0 (en) 2011-02-28
DOP2010000365A (es) 2011-01-15
NI201000211A (es) 2011-04-27
ZA201008871B (en) 2012-02-29
PE20110055A1 (es) 2011-02-11
EP2133074A1 (en) 2009-12-16
ECSP10010666A (es) 2011-01-31
CA2727326A1 (en) 2009-12-17
CO6280479A2 (es) 2011-05-20
CL2010001422A1 (es) 2011-05-13
KR20110026422A (ko) 2011-03-15
US20110166220A1 (en) 2011-07-07
MA32462B1 (fr) 2011-07-03
TW201002676A (en) 2010-01-16
EA201071378A1 (ru) 2011-06-30
WO2009150535A8 (en) 2010-12-23
CN102056603A (zh) 2011-05-11
AR072069A1 (es) 2010-08-04
MX2010013698A (es) 2011-02-23

Similar Documents

Publication Publication Date Title
UY31886A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente
CY1119177T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
SV2010003700A (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
BR112013015592A8 (pt) derivados de biciclo-[3.2.1]-octilamida e usos dos mesmos
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
TW200942530A (en) Pyridine compounds
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
RS52461B (en) FLUPENTIKSOL COMPOSITIONS
CL2010001421A1 (es) Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes.
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
CY1118117T1 (el) Νεα αμινο-πυρρολινικα παραγωγα και η χρηση τους στην προληψη ή και τη θεραπεια του μεταβολικου συνδρομου
RS53033B (en) VILDAGLIPTIN AND GLIMEPIRID COMBINATIONS
BR112013009647A2 (pt) derivado de vitamina, composição farmacêutica, agente terapêutico, e, composto
BR112013010061A2 (pt) "composição farmacêutica, composição e uso"
EP2627652A4 (en) NEW PYRIDYLBENZOXAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITION THEREFOR AND USE THEREOF
UY33381A (es) Dronedarona para prevencion de la hospitalizacion cardiovascular por fibrilación auricular
BRPI0908072A2 (pt) Composição farmacêutica, procedimento de preparação e uso da mesma
AR084975A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de la hospitalizacion cardiovascular o de la mortalidad en pacientes con fibrilacion auricular aislada
AR081392A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de hospitalizaciones cardiovasculares o muerte o sucesos cardiovasculares en pacientes con fibrilacion auricular permanente
TN2010000514A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
ECSP10010540A (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
CR11721A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de la mortalidad

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140602